Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767325 | 0.92 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL21484050 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL10429374 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL10429387 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL9540191 | 0.83 | — | — | |
| SCHEMBL16420274 | 0.83 | RAB9A (0.33) | — | |
| SCHEMBL20639270 | 0.83 | — | — | |
| SCHEMBL31725737 | 0.80 | RAB9A (0.38) | — | |
| SCHEMBL18692026 | 0.80 | — | — | |
| SCHEMBL23532681 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326936-A1 | ARTICLES INCLUDING SURFACE COATINGS AND METHODS TO PRODUCE THEM | MAXTERIAL INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO | 2025-07-10 | — | — | US | disclosed |
| US-12178851-B2 | Methods for administering STING agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| US-12173166-B2 | Articles including surface coatings and methods to produce them | MAXTERIAL, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| WO-2023192947-A2 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295827-A1 | COATINGS AND COATED SURFACES INCLUDING LOW-SURFACE ENERGY INORGANIC PARTICLES | MAXTERIAL INC (US) | 2023-09-21 | — | — | US | disclosed |
| CN-111417630-B | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-110167599-B | Compounds comprising self-sacrificing linking groups incorporating beta-galactosides | 英托赛尔公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| EP-2125859-B1 | ESTRATRIENE DERIVATIVES AND THEIR USES AS 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-8080540-B2 | Therapeutically active triazoles and their use | ABBOTT PRODUCTS GMBH (DE) | 2011-12-20 | — | — | US | disclosed |
| US-20110020837-A1 | Method for isolating or identifying a target protein interacting with a lipid in a cell | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2125859-A2 | ESTRATRIENE DERIVATIVES AND THEIR USES AS 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080146531-A1 | Therapeutically Active Triazoles and Their Use | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034796-A2 | ESTRATRIENE DERIVATIVES AND THEIR USES AS 17BETA-HYDR0XYSTER0ID DEHYDROGENASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-5466710-A | Heterobicycloalkanes as pesticidal compounds | ROUSSEL UCLAF (FR) | 1995-11-14 | — | — | US | disclosed |
| EP-0300797-B1 | Pesticidal compounds | ROUSSEL UCLAF (FR) | 1995-10-04 | — | — | EP | disclosed |
| US-5116862-A | Acetylenic trithiabicyclo(2.2.2)octanes | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| EP-0300797-A1 | Pesticidal compounds | ROUSSEL UCLAF (FR) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | TSHR 1048/4885TDP1 1654/4885ALDH1A1 3511/4885 |
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | GPR65, GPR52, GPR84 | TSHR 787/4885TDP1 4536/4885ALDH1A1 3369/4885 |
| US-20080146531-A1 | Therapeutically Active Triazoles and Their Use | HSD17B2, HSD17B3, HSD17B1 | TSHR 702/4885TDP1 1158/4885ALDH1A1 87/4885 |
| US-20110020837-A1 | Method for isolating or identifying a target protein interacting with a lipid in a cell | PLIN5, PLIN1, PLIN3 | TSHR 1564/4885TDP1 4301/4885ALDH1A1 3031/4885 |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | TSHR 1048/4885TDP1 1654/4885ALDH1A1 3511/4885 |
| US-12178851-B2 | Methods for administering STING agonists | STING1, CGAS, TLR9 | TSHR 2499/4885TDP1 286/4885ALDH1A1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.